Correction to: Leukemia (2014) 28, 1033–1040; doi:10.1038/leu.2013.305
Since the publication of this article it has been noted that there was an omission in the listing of conflict of interest. JM Bennett was listed as having no conflict of interest; however, the authors would like to correct this to read:
‘JMB is a consultant for and has received honoraria and contract monies as a consulting hematomorphologist from the Celgene Corporation’.
The authors apologise for any inconvenience caused by this error.
Author information
Consortia
Additional information
The online version of the original article can be found at 10.1038/leu.2013.305
Rights and permissions
About this article
Cite this article
List, A., Bennett, J., Sekeres, M. et al. Erratum: Extended survival and reduced risk of AML progression in erythroid-responsive lenalidomide-treated patients with lower-risk del(5q) MDS. Leukemia 29, 2452 (2015). https://doi.org/10.1038/leu.2015.312
Published:
Issue Date:
DOI: https://doi.org/10.1038/leu.2015.312
This article is cited by
-
Rethinking clinical trial endpoints in myelodysplastic syndromes
Leukemia (2019)
